Who is organising the trial?
The NHS-Galleri trial is organised and funded by a number of partner organisations.
The trial will be run by the Cancer Research UK & King’s College London Cancer Prevention Trials Unit, a team of cancer researchers and trial managers at King’s College London (King’s). They will coordinate this trial and analyse the results.
The study is in partnership with the National Health Service (NHS) England. They will provide follow-up and care related to the trial. The National Disease Registration Service will provide data for the trial.
GRAIL, LLC is a company in the United States that developed the Galleri® test. They have also set up a branch in the UK, GRAIL Bio UK Ltd. (GRAIL) which is the main funder and organiser of this trial.
Who are the Chief Investigators for the trial?
The Chief Investigators for the trial are Professor Richard Neal, a GP researcher who is interested in cancer screening, and Professor Charles Swanton, a cancer researcher at University College London and the Francis Crick Institute, and the Chief Clinician of Cancer Research UK.
Richard is a part time GP and Professor of Primary Care at the University of Exeter. His research examines the interface between primary care/general practice and cancer, with a particular focus in cancer diagnostics.
Professor Charles Swanton FRS FRCP is a clinician scientist. His research focuses on the management of metastatic cancer.
Who developed the Galleri test?
The Galleri test was developed by researchers at GRAIL in the US. Results from trials using the Galleri test suggest that the test can work well. The NHS now wants to do further work to understand whether the test works well enough to routinely offer it to people in the UK in the future.
Is anyone else involved?
GRAIL will use the services of logistics and supporting companies in the UK and outside the UK to help run the trial. They may handle blood samples and health information about people who take part in the trial. They will be required to do this safely and securely.